HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4...
Hence then, the article about akeso announces first patient enrolled in global phase iii trial of cadonilimab versus nivolumab in first line gastric cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer )
Also on site :
- At 68, Shaun Cassidy Jokes He’s the Rip Van Winkle of Teen Idols — ‘Looks More Like Shirley Jones Now’
- Jeff Ross Shares Throwback With Bob Saget, Norm MacDonald, and Gilbert Gottfried — But Fans Notice One Thing
- Brian Austin Green Vulnerably Shares ‘Challenging’ Times, Going Out ‘By Myself’ as Fiancée Sharna Burgess Shines on DWTS